DTM27 12-13 May, Berlin
House of Bio AI
House of Bio AI
House of Bio AI
The place where pharma and medtech leaders accelerate partnerships, shape regulation, and unlock capital.
/ Partners and participants in past events
Everyone who matters
in pharma and medtech.
/
What you can expect
Four tracks to scale pharma and medtech innovation in Europe.
Faster Scans, Lower Dose, More Patients: Sensing and Imaging for Diagnostics
Europe screens fewer people than its own guidelines recommend, and capacity is set by scan time and specialist hours. We put diagnostics manufacturers alongside sensor and model builders to cut scan time and dose while raising detection rate.
Betting on the Right Target: AI Target Discovery and Molecule Design
Choosing the wrong target commits years of discovery work to a small molecule or biologic that was never going to work. We bring search and evaluation teams together with the founders identifying high-probability targets and designing the molecules that hit them, to get collaborations signed rather than decks shown.
Fail in Silico, Not in Phase II: Predicting Human Response Before the Expensive Years
Programmes may clear every animal study and still fail once they reach patients, after the most expensive years are already spent. We convene translational medicine leaders with the teams predicting human response in silico, to move the go or no-go decision forward.
Turning a Batch into a Supply: Bioprocess, CMC and Manufacturing Capacity
Europe runs more than 250 advanced therapy trials and has fewer than 40 sites that could supply them. We match therapy developers and contract manufacturers with the sensors, analytics and automation builders who raise yield, to get more batches out of the clean rooms Europe already has.
/
What you can expect
Four tracks to scale pharma and medtech innovation in Europe.
Faster Scans, Lower Dose, More Patients: Sensing and Imaging for Diagnostics
Europe screens fewer people than its own guidelines recommend, and capacity is set by scan time and specialist hours. We put diagnostics manufacturers alongside sensor and model builders to cut scan time and dose while raising detection rate.
Betting on the Right Target: AI Target Discovery and Molecule Design
Choosing the wrong target commits years of discovery work to a small molecule or biologic that was never going to work. We bring search and evaluation teams together with the founders identifying high-probability targets and designing the molecules that hit them, to get collaborations signed rather than decks shown.
Fail in Silico, Not in Phase II: Predicting Human Response Before the Expensive Years
Programmes may clear every animal study and still fail once they reach patients, after the most expensive years are already spent. We convene translational medicine leaders with the teams predicting human response in silico, to move the go or no-go decision forward.
Turning a Batch into a Supply: Bioprocess, CMC and Manufacturing Capacity
Europe runs more than 250 advanced therapy trials and has fewer than 40 sites that could supply them. We match therapy developers and contract manufacturers with the sensors, analytics and automation builders who raise yield, to get more batches out of the clean rooms Europe already has.
/
What you can expect
Four tracks to scale pharma and medtech innovation in Europe.
Faster Scans, Lower Dose, More Patients: Sensing and Imaging for Diagnostics
Europe screens fewer people than its own guidelines recommend, and capacity is set by scan time and specialist hours. We put diagnostics manufacturers alongside sensor and model builders to cut scan time and dose while raising detection rate.
Betting on the Right Target: AI Target Discovery and Molecule Design
Choosing the wrong target commits years of discovery work to a small molecule or biologic that was never going to work. We bring search and evaluation teams together with the founders identifying high-probability targets and designing the molecules that hit them, to get collaborations signed rather than decks shown.
Fail in Silico, Not in Phase II: Predicting Human Response Before the Expensive Years
Programmes may clear every animal study and still fail once they reach patients, after the most expensive years are already spent. We convene translational medicine leaders with the teams predicting human response in silico, to move the go or no-go decision forward.
Turning a Batch into a Supply: Bioprocess, CMC and Manufacturing Capacity
Europe runs more than 250 advanced therapy trials and has fewer than 40 sites that could supply them. We match therapy developers and contract manufacturers with the sensors, analytics and automation builders who raise yield, to get more batches out of the clean rooms Europe already has.
/
WHY JOIN
Where pharma and medtech corporates, innovators and investors move new medicines and diagnostics into use.
Fast track commercial partnerships with high-intent matchmaking
Meetings are matched and booked before you arrive with the people who hold the authority, mandate and budget.
Get exclusive procurement intelligence from the best speakers and exhibitors
Engage with the corporate leaders setting strategy, the founders building what comes next, the investors writing cheques and the policymakers writing the rules.
Shape European regulation with invite-only summits
European ministers, corporate CEOs, unicorn founders, and tier-1 investors start the joint initiatives that move the industry and shape its regulatory environment.
Grow with customers you didn't expect
Pharma and medtech innovators meet robotics unicorns and advanced materials giants. At DTM27, every House next door is a potential customer.
/
WHY JOIN
Where pharma and medtech corporates, innovators and investors move new medicines and diagnostics into use.
Fast track commercial partnerships with high-intent matchmaking
Meetings are matched and booked before you arrive with the people who hold the authority, mandate and budget.
Get exclusive procurement intelligence from the best speakers and exhibitors
Engage with the corporate leaders setting strategy, the founders building what comes next, the investors writing cheques and the policymakers writing the rules.
Shape European regulation with invite-only summits
European ministers, corporate CEOs, unicorn founders, and tier-1 investors start the joint initiatives that move the industry and shape its regulatory environment.
Grow with customers you didn't expect
Pharma and medtech innovators meet robotics unicorns and advanced materials giants. At DTM27, every House next door is a potential customer.
/
WHY JOIN
Where pharma and medtech corporates, innovators and investors move new medicines and diagnostics into use.
Fast track commercial partnerships with high-intent matchmaking
Meetings are matched and booked before you arrive with the people who hold the authority, mandate and budget.
Get exclusive procurement intelligence from the best speakers and exhibitors
Engage with the corporate leaders setting strategy, the founders building what comes next, the investors writing cheques and the policymakers writing the rules.
Shape European regulation with invite-only summits
European ministers, corporate CEOs, unicorn founders, and tier-1 investors start the joint initiatives that move the industry and shape its regulatory environment.
Grow with customers you didn't expect
Pharma and medtech innovators meet robotics unicorns and advanced materials giants. At DTM27, every House next door is a potential customer.
/ Partner with US
Host the House of Bio AI
Your opportunity to co-create the most impactful industry marketplace in Europe.
01
Make it your house
Align the entire house with your brand. Put yourself at the center of the entire industry conversation.
02
Co-author the agenda
Co-shape key themes discussed by industry leaders. Lead the opening keynote and bring your tier-1 customers on stage with you.
03
Attract your ideal audience
DTM convenes the buyers, builders and investors who move the needle. Get their full attention with meetings tailored to your ICP.
04
Reach beyond the room
Get your name front-and-center on the DTM27 insights and reports reaching the wider industry.
/ Partner with US
Host the House of Bio AI
Your opportunity to co-create the most impactful industry marketplace in Europe.
01
Make it your house
Align the entire house with your brand. Put yourself at the center of the entire industry conversation.
02
Co-author the agenda
Co-shape key themes discussed by industry leaders. Lead the opening keynote and bring your tier-1 customers on stage with you.
03
Attract your ideal audience
DTM convenes the buyers, builders and investors who move the needle. Get their full attention with meetings tailored to your ICP.
04
Reach beyond the room
Get your name front-and-center on the DTM27 insights and reports reaching the wider industry.
/ Partner with US
Host the House of Bio AI
Your opportunity to co-create the most impactful industry marketplace in Europe.
01
Make it your house
Align the entire house with your brand. Put yourself at the center of the entire industry conversation.
02
Co-author the agenda
Co-shape key themes discussed by industry leaders. Lead the opening keynote and bring your tier-1 customers on stage with you.
03
Attract your ideal audience
DTM convenes the buyers, builders and investors who move the needle. Get their full attention with meetings tailored to your ICP.
04
Reach beyond the room
Get your name front-and-center on the DTM27 insights and reports reaching the wider industry.
Join the House of Bio AI to shape European competitiveness.
12-13 May 2027, Wilhelm Studios Berlin
Join the House of Bio AI to shape European competitiveness.
12-13 May 2027, Wilhelm Studios Berlin
Join the House of Bio AI to shape European competitiveness.
12-13 May 2027, Wilhelm Studios Berlin
DTM27
The engine for deep tech and AI commercialisation in Europe. 6 Houses, 20,000 one-on-ones, €400B in the room.
© 2026 Deep Tech Momentum
DTM27
The engine for deep tech and AI commercialisation in Europe. 6 Houses, 20,000 one-on-ones, €400B in the room.
© 2026 Deep Tech Momentum
DTM27
The engine for deep tech and AI commercialisation in Europe. 6 Houses, 20,000 one-on-ones, €400B in the room.
© 2026 Deep Tech Momentum